From the Department of Anesthesiology & Perioperative Medicine.
Cardiovascular-ICU.
Anesth Analg. 2019 Jul;129(1):e1-e4. doi: 10.1213/ANE.0000000000003648.
Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.
羟钴胺素（维生素 B12a）是一种新兴的治疗体外循环（CPB）相关血管扩张性综合征（VS）的方法。鉴于其成本和稀缺性，制定了一项机构指南，将其作为疑似 VS 病例的抢救治疗方法。对接受 B12a 的 24 例 CPB 后患者的血流动力学变量和血管加压药需求进行了回顾。尽管 VS 的指南标准不一致，但 B12a 给药后观察到血流动力学参数和血管加压药需求的有利变化。这些发现支持在 CPB 相关 VS 患者中继续研究 B12a。
